AdaptHealth Corp vs CVS Health Corp — how do they compare? AdaptHealth Corp trades at $5.66 (market cap $759.10M), while CVS Health Corp trades at $93.7 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 161.2× AdaptHealth Corp's market cap, and CVS Health Corp pays a 2.78% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | CVS | |
|---|---|---|
Market Cap | $759.10M | $122.36B |
Sector | Health | Health |
52-Week High | $13.38 | $110.60 |
52-Week Low | $5.22 | $65.51 |
Enterprise Value | $2.78B | $184.71B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.69, down 5.87% in the last 24 hours, reflecting negative sentiment after recent earnings misses and lowered guidance. The stock shows a bearish technical signal with support near $5, while fundamentals reveal revenue of $3.24 billion in 2025 but a net loss of $70.79 million, with profitability metrics like net margin at -6.82% indicating operational challenges. Recent news highlights multiple law firm investigations into potential securities fraud following disappointing Q2 2026 results.
The outlook for AHCO is cautious due to persistent earnings underperformance and rising costs from fixed-price contracts. While analyst consensus remains bullish with a $11.00 price target, significant risks include ongoing legal scrutiny, margin pressure, and execution uncertainties. Investors should weigh the high institutional buy ratings against fundamental weaknesses and recent negative developments.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →